Evidence map›Paper›PMID 25691567›Full record

ArticleThe Journal of biological chemistry2015

Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.

Rangasamy Sneha Priya, Menon Veena, Irene Kalisz, Stephen Whitney, Dhopeshwarkar Priyanka, Celia C LaBranche, Mullapudi Sri Teja, David C Montefiori, Ranajit Pal, Sundarasamy Mahalingam and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Rangasamy Sneha PriyaFrom the Laboratory of Molecular Virology and Cell Biology, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, India.
Menon VeenaAdvanced Bioscience Laboratories Inc., Rockville, Maryland 20850, and.
Irene KaliszAdvanced Bioscience Laboratories Inc., Rockville, Maryland 20850, and.
Stephen WhitneyAdvanced Bioscience Laboratories Inc., Rockville, Maryland 20850, and.
Dhopeshwarkar PriyankaAdvanced Bioscience Laboratories Inc., Rockville, Maryland 20850, and.
Celia C LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
Mullapudi Sri TejaFrom the Laboratory of Molecular Virology and Cell Biology, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, India.
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
Ranajit PalAdvanced Bioscience Laboratories Inc., Rockville, Maryland 20850, and.
Sundarasamy MahalingamFrom the Laboratory of Molecular Virology and Cell Biology, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, India, mahalingam@iitm.ac.in.
Vaniambadi S KalyanaramanAdvanced Bioscience Laboratories Inc., Rockville, Maryland 20850, and.
Duke Medical Center · USDuke University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human immunodeficiency virus type 1 (HIV-1) isolates from India mainly belong to clade C and are quite distinct from clade C isolates from Africa in terms of their phylogenetic makeup, serotype, and sensitivity to known human broadly neutralizing monoclonal antibodies. Because many of these properties are associated with the envelope proteins of HIV-1, it is of interest to study the envelope proteins of Indian clade C isolates as part of the ongoing efforts to develop a vaccine against HIV-1. To this end, we purified trimeric uncleaved gp145 of a CCR5 tropic Indian clade C HIV-1 (93IN101) from the conditioned medium of 293 cells. The purified protein was shown to be properly folded with stable structure by circular dichroism. Conformational integrity was further demonstrated by its high affinity binding to soluble CD4, CD4 binding site antibodies such as b12 and VRC01, quaternary epitope-specific antibody PG9, and CD4-induced epitope-specific antibody 17b. Sera from rabbits immunized with gp145 elicited high titer antibodies to various domains of gp120 and neutralized a broad spectrum of clade B and clade C HIV-1 isolates. Similar to other clade B and clade C envelope immunogens, most of the Tier 1 neutralizing activity could be absorbed with the V3-specific peptide. Subsequent boosting of these rabbits with a clade B HIV-1 Bal gp145 resulted in an expanded breadth of neutralization of HIV-1 isolates. The present study strongly supports the inclusion of envelopes from Indian isolates in a future mixture of HIV-1 vaccines.

Indexed as

AnimalsBinding SitesCHO CellsCircular DichroismCricetinaeCricetulusEnzyme-Linked Immunosorbent AssayHEK293 CellsHIV-1HIV AntigensHumansViral Envelope ProteinsHIV AntigensViral Envelope ProteinsAIDSAntigenCell Surface ProteinHuman Immunodeficiency Virus (HIV)Vaccine Development

Identifiers

PMID25691567
PMCPMC4423705
OpenAlexW2029011728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.